drugset / Trial / NCT06630325
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
Phase 2
Terminated
6 enrolled
OHSU Knight Cancer Institute
AstraZeneca · collabEli Lilly and Company · collabOregon Health and Science University · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase II trial tests the how well a precision medicine approach (serial measurements of molecular and architectural response to therapy \[SMMART\])-adaptive clinical treatment \[ACT\]) works in treating patients with sarcoma, prostate, breast, ovarian or pancreatic cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). SMMART testing uses genetic and protein tests to learn how cancer changes and to understand what drugs may work against a person's cancer or why drugs stop working. These test results are reviewed by a group of physicians and scientists during a SMMART tumor board who then recommend precision therapy.
Timeline
- Start
- 2025-06-24
- Primary completion
- 2026-03-11
- Completion
- 2026-03-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | Oral |
| Subject | Exemestane | Small molecule | — | Oral |
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Subject | Letrozole | Other / unclassified | — | Oral |
| Subject | Osimertinib | Small molecule | — | Oral |
| Subject | Pemetrexed | Small molecule | — | Intravenous |
| Subject | Tamoxifen | Small molecule | — | Oral |